# A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

> **NCT06095089** · PHASE1 · RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 355 (estimated)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** JNJ-78278343
- **DRUG:** JNJ-87189401
- **DRUG:** Apalutamide
- **DRUG:** Lutetium Lu-177 Vipivotide Tetraxetan
- **DRUG:** JNJ-101556143

## Key facts

- **NCT ID:** NCT06095089
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2027-06-21
- **Final completion:** 2028-06-28
- **Target enrollment:** 355 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06095089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06095089, "A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06095089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*